Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered ...

Ozempic was originally approved to treat people with Type 2 diabetes, but demand has surged because of the drug’s weight-loss ...

About 422 million people worldwide have diabetes, according to the WHO, and most of them live in low- or middle-income ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...

A new study shows that joining a weight loss support group such as Slimming World can quickly restore self-belief, ...

Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular ...

Which biotechs are most likely to be acquired near-term? We asked Seeking Alpha analysts Edmund Ingham and Terry Chrisomalis for their thoughts on the topic. Read more here.

Viking Therapeutics ( VKTX 4.30%) didn't exactly capture investors' hearts in the final month of 2024. The biotech company's ...

For Robert F. Kennedy Jr., the activist whom President-elect Donald Trump will nominate to serve as the secretary of health and human services, the solution to obesity in America – now at 40% of ...

The Centers for Medicare & Medicaid Services has proposed a rule expanding Medicare and Medicaid patients’ access to anti-obesity drugs such as GLP-1s.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would ...